The Impact of the Preparation Method on the Properties of Orodispersible Films with Aripiprazole: Electrospinning vs. Casting and 3D Printing Methods.
3D printing
aripiprazole
electrospinning
orodispersible films
solvent casting
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
22 Jul 2021
22 Jul 2021
Historique:
received:
28
06
2021
revised:
15
07
2021
accepted:
20
07
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
Orodispersible films (ODFs) address the needs of pediatric and geriatric patients and people with swallowing difficulties due to fast disintegration in the mouth. Typically, they are obtained using the solvent casting method, but other techniques such as 3D printing and electrospinning have already been investigated. The decision on the manufacturing method is of crucial importance because it affects film properties. This study aimed to compare electrospun ODFs containing aripiprazole and polyvinyl alcohol with films prepared using casting and 3D printing methods. Characterization of films included DSC and XRD analysis, microscopic analysis, the assessment of mechanical parameters, disintegration, and dissolution tests. Simplified stability studies were performed after one month of storage. All prepared films met acceptance criteria for mechanical properties. Electrospun ODFs disintegrated in 1.0 s, which was much less than in the case of other films. Stability studies have shown the sensitivity of electrospun films to the storage condition resulting in partial recrystallization of ARP. These changes negatively affected the dissolution rate, but mechanical properties and disintegration time remained at a desirable level. The results demonstrated that electrospun fibers are promising solutions that can be used in the future for the treatment of patients with swallowing problems.
Identifiants
pubmed: 34452083
pii: pharmaceutics13081122
doi: 10.3390/pharmaceutics13081122
pmc: PMC8401512
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerstwo Nauki i Szkolnictwa Wyższego
ID : N42/DBS/000130
Références
Materials (Basel). 2020 Nov 04;13(21):
pubmed: 33158192
Materials (Basel). 2019 Aug 04;12(15):
pubmed: 31382665
Eur J Pharm Sci. 2015 Jul 30;75:81-90
pubmed: 25889975
Eur J Pharm Sci. 2018 May 30;117:236-244
pubmed: 29499348
Neuropharmacology. 2012 Feb;62(2):765-74
pubmed: 21925189
Pharm Res. 2018 Jul 11;35(9):176
pubmed: 29998405
Int J Pharm. 2020 Feb 25;576:118963
pubmed: 31857185
Pharmaceutics. 2020 May 21;12(5):
pubmed: 32455717
Profiles Drug Subst Excip Relat Methodol. 2013;38:35-85
pubmed: 23668402
Int J Pharm. 2014 Dec 30;477(1-2):369-79
pubmed: 25455779
Pharm Res. 2018 Jan 5;35(1):16
pubmed: 29305665
J Pharm Biomed Anal. 2016 Jan 5;117:298-303
pubmed: 26397209
J Agric Food Chem. 2015 Nov 11;63(44):9831-8
pubmed: 26499787
Eur Child Adolesc Psychiatry. 2012 Jul;21(7):361-8
pubmed: 22447196
Chem Rev. 2019 Apr 24;119(8):5298-5415
pubmed: 30916938
Pharm Dev Technol. 2017 Mar;22(2):237-245
pubmed: 27346557
AAPS PharmSciTech. 2019 Jan 7;20(2):52
pubmed: 30617660
Int J Pharm. 2012 Nov 15;438(1-2):287-95
pubmed: 22989976
Int J Pharm. 2019 Apr 20;561:43-46
pubmed: 30772459
Int J Pharm. 2020 Jun 30;584:119405
pubmed: 32387310
Eur J Pharm Biopharm. 2019 Mar;136:93-101
pubmed: 30660692
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):996-1008
pubmed: 16678954
J Control Release. 2020 Oct 10;326:482-509
pubmed: 32721525
Biomed Mater. 2017 Dec 28;13(1):015019
pubmed: 28895559
Sci Rep. 2018 Mar 22;8(1):5058
pubmed: 29568048
Int J Pharm. 2015 Oct 15;494(1):23-30
pubmed: 26241751
Eur J Pharm Biopharm. 2018 Apr;125:131-140
pubmed: 29355687
Expert Opin Pharmacother. 2011 Mar;12(4):635-40
pubmed: 21294670
Profiles Drug Subst Excip Relat Methodol. 2012;37:1-29
pubmed: 22469315
Colloids Surf B Biointerfaces. 2013 Mar 1;103:182-8
pubmed: 23201736
Int J Pharm. 2020 Feb 15;575:118955
pubmed: 31843552
Int J Pharm. 2017 Jan 30;517(1-2):329-337
pubmed: 27988377
Int J Pharm. 2015 May 15;485(1-2):70-6
pubmed: 25746737
Int J Pharm. 2017 Feb 25;518(1-2):242-252
pubmed: 28007543
J Control Release. 2018 Dec 28;292:91-110
pubmed: 30118788
J Pharm Sci. 2020 Dec;109(12):3551-3568
pubmed: 33035541
Int J Pharm. 2017 Nov 30;533(2):413-420
pubmed: 28552800
Int J Pharm. 2012 Jul 1;430(1-2):197-206
pubmed: 22525080
Eur J Pharm Sci. 2017 Jan 1;96:290-298
pubmed: 27629498
Expert Opin Drug Deliv. 2011 Mar;8(3):299-316
pubmed: 21284577
Clin Ther. 2015 Dec 1;37(12):2772-9
pubmed: 26546405
Biomater Sci. 2016 Jun 24;4(6):922-32
pubmed: 27048889
Eur J Pharm Biopharm. 2020 Sep;154:283-289
pubmed: 32634573
Eur J Pharm Sci. 2019 Mar 15;130:91-99
pubmed: 30684658
J Pharm Sci. 2020 Oct;109(10):2925-2942
pubmed: 32565356
Eur J Pharm Biopharm. 2017 Oct;119:81-90
pubmed: 28596037
J Control Release. 2015 May 28;206:1-19
pubmed: 25747406
Eur J Pharm Sci. 2016 Sep 20;92:146-55
pubmed: 27402100
Eur J Pharm Biopharm. 2017 Oct;119:283-299
pubmed: 28690200
Int J Pharm. 2017 May 15;523(1):327-335
pubmed: 28302515
J Pharm Sci. 2018 Apr;107(4):1076-1085
pubmed: 29208374
Pharmaceutics. 2021 Jan 19;13(1):
pubmed: 33477855
J Biomater Appl. 2014 Jan;28(5):779-89
pubmed: 23520360
Ther Deliv. 2019 Jul;10(7):443-464
pubmed: 31264527
Eur J Pharm Biopharm. 2018 Nov;132:50-61
pubmed: 30201569
J Pharm Sci. 2009 Jun;98(6):2010-26
pubmed: 19009597
Int J Pharm. 2017 Jul 15;527(1-2):151-160
pubmed: 28549972
Expert Opin Drug Deliv. 2016;13(4):493-506
pubmed: 26559519